#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3482	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2864	344.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	2193	2193	T	501	T	430	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3482	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2864	344.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1927	1927	C	451	C,A	358,5	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6140	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4038	433.8	0	.	n	.	0	T695C	SNP	695	695	T	1267	1267	C	475	C	400	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6140	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4038	433.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2543	2543	C	499	C	422	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6140	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4038	433.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2617	2617	A	514	A	429	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6140	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4038	433.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3169	3169	C	515	C,G	423,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	470	folP	855	855	99.88	folP.l6.c4.ctg.1	2058	65.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1244	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3894	90.5	0	.	p	.	0	A92P	NONSYN	274	276	GCA	760	762	CCA	93;91;89	C;C;A	74;74;71	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1244	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3894	90.5	1	SNP	p	S91F	1	.	.	271	273	TTC	757	759	TTC	94;96;94	T;T;C	79;74;77	gyrA.WHO_G_01105:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1244	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3894	90.5	1	SNP	p	D95N	0	.	.	283	285	GAC	769	771	GAC	91;92;92	G;A;C	74;78;74	gyrA.WHO_G_01105:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1244	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3894	90.5	1	SNP	p	D95G	0	.	.	283	285	GAC	769	771	GAC	91;92;92	G;A;C	74;78;74	gyrA.WHO_G_01105:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	492	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1775	80.5	1	SNP	p	G45D	1	.	.	133	135	GAC	747	749	GAC	144;145;144	G;A;C,G	120;119;119,1	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	334	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1290	73.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1092	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3400	91.6	1	SNP	p	D86N	0	.	.	256	258	GAC	794	796	GAC	72;72;72	G;A;C	65;61;59	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1092	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3400	91.6	1	SNP	p	S87W	0	.	.	259	261	AGT	797	799	AGT	72;74;74	A;G,T;T	56;63,1;62	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1092	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3400	91.6	1	SNP	p	S87I	0	.	.	259	261	AGT	797	799	AGT	72;74;74	A;G,T;T	56;63,1;62	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1092	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3400	91.6	1	SNP	p	S87R	0	.	.	259	261	AGT	797	799	AGT	72;74;74	A;G,T;T	56;63,1;62	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1092	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3400	91.6	1	SNP	p	S88P	0	.	.	262	264	TCC	800	802	TCC	74;74;76	T,G;C;C	63,1;66;67	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1024	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3097	94.4	0	.	p	.	0	P456S	NONSYN	1366	1368	CCC	1865	1867	TCC	116;117;117	T,G;C;C	94,1;99;97	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1024	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3097	94.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1727	1729	GGC	129;127;127	G;G;C	105;102;101	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	A311V	0	.	.	931	933	GCC	1436	1438	GCC	135;136;135	G;C;C	113;113;115	penA.27.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	I312M	1	.	.	934	936	ATG	1439	1441	ATG	135;132;132	A;T;G	115;112;108	penA.27.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	T316P	0	.	.	946	948	ACC	1451	1453	ACC	135;135;135	A,C;C;C	114,1;116;116	penA.27.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	V316T	1	.	.	946	948	ACC	1451	1453	ACC	135;135;135	A,C;C;C	114,1;116;116	penA.27.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1952	1954	ACC	116;117;116	A;C;C	95;96;96	penA.27.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2006	2008	GCG	111;110;110	G;C;G	88;87;85	penA.27.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2006	2008	GCG	111;110;110	G;C;G	88;87;85	penA.27.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2129	2131	GGT	115;114;114	G;G;T	97;95;95	penA.27.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2138	2140	AGC	114;114;114	A;G;C	92;96;98	penA.27.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	980	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2794	99.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2156	2158	CCG	110;111;112	C;C;G	96;97;99	penA.27.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1310	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3447	108.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1803	1805	CCG	102;105;105	C,T;C,A;G,C	84,1;83,1;87,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	562	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2345	68.7	0	.	p	.	0	S22G	NONSYN	64	66	AGC	674	676	GGC	107;107;106	G;G;C	87;89;88	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	562	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2345	68.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	856	856	C	81	C	64	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	841	843	AAG	152;152;152	A;A;G	123;127;126	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1117	1119	GAT	140;140;139	G;A;T	118;116;115	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1120	1122	GGT	139;138;138	G;G,T;T	117;112,1;113	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1126	1128	GCT	136;136;136	G;C;T,C	112;114;113,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1135	1137	ATG	131;131;131	A;T;G	107;108;109	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1252	1254	ACG	120;120;122	A;C,A;G,T	101;99,1;99,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1258	1260	GTT	118;119;119	G;T;T	99;103;103	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1372	1374	AAC	116;114;113	A;A;C	97;95;93	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	1	SNP	p	A121D	1	.	.	361	363	GAC	844	846	GAC	153;153;153	G;A,C;C,A	126;122,1;121,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	698	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	2156	91.3	1	SNP	p	D121N	0	.	.	361	363	GAC	844	846	GAC	153;153;153	G;A,C;C,A	126;122,1;121,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2332	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5282	126.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2256	2258	CAT	134;133;133	C;A;T	108;107;103	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	384	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1329	81.9	1	SNP	p	V57M	1	.	.	169	171	ATG	643	645	ATG	159;159;158	A;T;G	129;128;127	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
